|

Trastuzumab Subcutaneous Subcutaneous Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Herceptin Hylecta, Trastuzumab and hyaluronidase-oysk

Pipeline

Phase 2: 1

Top Sponsors

  • Dana-Farber Cancer Institute1

Indications

  • Stage IV Breast Cancer1
  • Estrogen Receptor-positive Breast Cancer1
  • Breast Cancer, Metastatic1
  • HER2-positive Breast Cancer1
  • Breast Cancer Female1

Boston, Massachusetts1 trial

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.